Despite the failed multicenter trial, there is a broad consensus that EPO remains a promising candidate for neuroprotective therapy, but extensive molecular and cellular preclinical investigations are needed prior to any potential clinical use in stroke patients. This evidence concerns the gene EPO and Stroke.